El interés en corto de Perfect Moment da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Perfect Moment. Los datos de interés en corto se actualizan cada dos semanas.

Perfect Moment (AMEX:PMNT) Bolsa, Informe de interés en corto

Perfect Moment

Perfect Moment Ltd is a company which is a luxury lifestyle brand that combines fashion and technical performance for its ranges of skiwear, outerwear, swimwear, and activewear. It operates at the intersection of luxury fashion and multi-channel commerce. Although the Company is organized fundamentally as one business segment which is product sales, the Company's revenues are primarily split between three geographic areas which are the U. S., Europe, and the UK.

Perfect Moment Ltd

News

IFRX

InflaRx Doses First Patient In Phase 2a Basket Study In Chronic Spontaneous Urticaria And Hidradenitis Suppurativa, Investigating Oral C5aR Inhibitor, INF904

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Alumis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMS#NASDAQ">ALMS</a>) with a Buy and maintains $26 price target.

Price Target

Reiteration

Analyst Ratings

ALMS

HC Wainwright & Co. Reiterates Buy on Alumis, Maintains $26 Price Target

BLDP

Ballard Announces Multiple Orders Totaling Over 6 MW Of Fuel Cell Engines For European Bus Market

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) with a Buy and maintains $10 price target.

SGMO

HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $10 Price Target

LODE

Comstock Sells Northern Mining Targets To Mackay Precious Metals Inc.  For An Aggregate Purchase Price Of $2.75M

Management

Travel Leisure Says CFO Michael A. Hug Notified His Intention To Retire During FY25

PMGC Holdings Inc. (formerly known as Elevai Labs Inc.) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELAB#NASDAQ">ELAB</a>) (before and after the redomestication, the "Company" or "we") announced today that it plans to effectuate a strategic reorganization effective on December 20, 2024. This reorganization will include changing the Company's name from Elevai Labs Inc. to PMGC Holdings Inc. and redomiciling from Delaware to Nevada. After this reorganization, the Company will continue to trade on The Nasdaq Stock Market&nbsp;("Nasdaq") under the ticker symbol "ELAB."&nbsp;The redomestication and name change will be effective on Nasdaq at the opening of business on December 23, 2024.

ELAB

Elevai Labs Inc. Announces Anticipated Name Change To PMGC Holdings Inc. And Redomicile To Nevada

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) on Friday announced a recall affecting nearly 700,000 vehicles, leading to a notable drop in its stock price during the premarket.
What Happened: Tesla experienced a 5.04% drop in its stock price during Friday&#8217;s premarket, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, after a recall of 694,304 vehicles in the U.S. due to a tire pressure monitoring system (TPMS) issue that could potentially increase the risk of accidents, as per NHTSA.
The TPMS warning light may&nbsp;fail to stay illuminated between drive cycles, potentially leaving drivers unaware of low tire pressure, as noted in the recall acknowledgment. This malfunction could lead to vehicles being operated with improperly inflated tires, heightening the risk of accidents.
See Also:&nbsp;<a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42528919/how-to-earn-500-a-month-from-apple-stock-4?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">How To Earn $500 A Month From Apple Stock</a>
The recall affects certain Model 3, Model Y, and Cybertruck vehicles.&nbsp;Tesla&nbsp;plans to address the issue through an over-the-air software update, minimizing disruption for owners. The automaker&#8217;s vehicles comprised&nbsp;21% of all U.S. recalls&nbsp;in the first three quarters&nbsp;of the year, as reported by recall management firm&nbsp;BizzyCar.
Meanwhile, Tesla has a consensus price target of&nbsp;$280.41&nbsp;based on the ratings of&nbsp;33&nbsp;analysts, as per <a href="https://pro.benzinga.com">Benzinga Pro</a>. As per the&nbsp;three most recent analyst ratings were released by&nbsp;Baird, Mizuho, and Goldman Sachs, respectively. The average price target has been set at $446.67&nbsp;with an implied&nbsp;7.26%&nbsp;upside for Tesla from these most recent analyst ratings.
Despite the high number of recalls, most problems with&nbsp;Tesla&nbsp;vehicles are typically resolved via software updates. In the September quarter alone, the company recalled 1,858,774 vehicles, the most in the U.S. In November,&nbsp;Tesla&nbsp;recalled 2,400 Cybertruck units due to a faulty part that could cause power loss, marking the sixth recall for the model this year.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/quote/TSLA/analyst-ratings"><img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/20071959/Screenshot-2024-12-20-at-5.49.31%E2%80%AFPM-1024x394.png" alt="" class="wp-image-701554" /></a></figure>
Why It Matters: The latest recall highlights ongoing challenges for&nbsp;Tesla&nbsp;in maintaining vehicle safety standards. The company has been proactive in addressing issues, often through software updates, but the frequency of recalls remains a concern. Notably,&nbsp;<a href="https://www.benzinga.com/tech/24/11/41934708/tesla-recalls-over-2400-cybertrucks-in-us">Tesla recently recalled over 2,400 Cybertrucks</a>&nbsp;due to a drive inverter fault that could lead to power loss, as reported by the National Highway Traffic Safety Administration (NHTSA). This issue was identified after a customer complaint in July, prompting an investigation and subsequent recall.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/24/12/42545419/bitcoin-ethereum-dogecoin-stay-muted-before-feds-interest-rate-decision-analyst-says-btc-in-parabolic-phase-reveals-its-duration?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Bitcoin, Ethereum, Dogecoin Stay Muted Before Fed&#8217;s Interest Rate Decision: Analyst Says BTC In Parabolic Phase, Reveals Its Duration</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image via Shutterstock

Equities

Pre-Market Outlook

Markets

General

TSLA

Tesla Stock Falls Over 5% During Pre-Market After Elon Musk-Led EV Giant Recalls Nearly 700,000 Vehicles

The most oversold stocks in the information technology sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Axcelis Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACLS#NASDAQ">ACLS</a>)</h3>
<ul>
<li>On Nov. 6, Axcelis Technologies posted better-than-expected quarterly earnings. President and CEO Russell Low commented, &#8220;Axcelis executed well in the third quarter with results relatively in-line with our expectations. While we anticipate a near term digestion of mature node capacity through the first half of 2025, customer engagement is strong and our long-term growth opportunity remains squarely intact highlighted by attractive secular growth in silicon carbide, a cyclical recovery in our memory and general mature markets, market share gains in advanced logic and regional penetration of the Japan market.&#8221; The company's stock fell around 9% over the past five days and has a <a href="https://www.benzinga.com/quote/ACLS">52-week low of $68.79</a>.</li>
<li>RSI Value: 29.60&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>ACLS Price Action: Shares of Axcelis Technologies fell 2.5% to close at $69.18 on Thursday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122024&amp;t=be2bearmibe3na1"> latest ACLS news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="912" height="838" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/20042416/image-176.png" alt="" class="wp-image-701292" style="width:590px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/20042416/image-176.png 912w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/20042416/image-176-300x276.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/20042416/image-176-768x706.png 768w" sizes="(max-width: 912px) 100vw, 912px" /></a></figure>
<h3 class="wp-block-heading">Applied Materials Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>On Dec. 6, Wells Fargo analyst Joseph Quatrochi maintained the stock with an Overweight rating and lowered the price target from $220 to $210.. The company's stock fell around 4% over the past five days and <a href="https://www.benzinga.com/quote/AMAT">has a 52-week low</a> of $148.06.</li>
<li>RSI Value: 29.31</li>
<li>AMAT Price Action: Shares of Applied Materials fell 2.4% to close at $161.44 on Thursday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122024&amp;t=be2bearmibe3na1"> trend in AMAT stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="917" height="847" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/20043922/image-177.png" alt="" class="wp-image-701321" style="width:615px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/20043922/image-177.png 917w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/20043922/image-177-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/20043922/image-177-768x709.png 768w" sizes="(max-width: 917px) 100vw, 917px" /></a></figure>
<h3 class="wp-block-heading">Microchip Technology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>)</h3>
<ul>
<li>On Dec. 11, Stifel analyst Nathan Jones maintained A.O. Smith with a Buy and lowered the price target from $91 to $90. The company's stock fell around 14% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/MCHP">low of $55.90</a>.</li>
<li>RSI Value: 27.86</li>
<li>MCHP Price Action: Shares of Microchip Technology fell 0.3% to close at $55.99 on Thursday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122024&amp;t=be2bearmibe3na1">breakout in MCHP shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="908" height="833" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/20044118/image-178.png" alt="" class="wp-image-701323" style="width:635px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/20044118/image-178.png 908w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/20044118/image-178-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/20044118/image-178-768x705.png 768w" sizes="(max-width: 908px) 100vw, 908px" /></a></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42582254/top-3-consumer-stocks-you-may-want-to-dump-this-quarter">Top 3 Consumer Stocks You May Want To Dump This Quarter</a></li>
</ul>

Long Ideas

Trading Ideas

ACLS

AMAT

MCHP

Top 3 Tech Stocks That Could Blast Off In Q4

Knife River Announced Today That It Has Entered Into A Definitive Agreement To Acquire Strata Corporation; Based On Strata's Projected 2025 Adj. EBITDA, The Purchase Price Of $454M Reflects A Multiple In The High Single Digits

The company entered securities purchase agreement with certain institutional investors for the purchase and sale of 3.33 million shares of common stock (or common stock equivalents) and warrants to purchase up to an aggregate of 5 million shares of its common stock at a combined public offering price of $1.50 per share of common stock (or common stock equivalent) and associated warrant in a registered direct offering.
The common warrants will have an exercise price of $1.50 per share, are exercisable immediately, and have a term of exercise equal to five years from the date of initial exercise.
The Company intends to use the net proceeds from this offering for general corporate purposes.

Offerings

FNGR

FingerMotion Enters Definitive Securities Purchase Agreement For $5M Registered Direct Offering

QNTM

Quantum BioPharma Says It Diversified Treasury With The Purchase Of Usd $1M Of Bitcoin And Other Cryptocurrencies And To Allow For Future Financings And Other Transactions In Cryptocurrency

Strata is a construction materials and contracting services provider in North Dakota and northwestern Minnesota. Based on Strata's projected 2025 Adj. EBITDA, the purchase price reflects a multiple in the high single digits.
The transaction is expected to close in the first half of 2025, subject to regulatory approval and customary closing conditions. Knife River expects to use cash on hand and the proceeds from the issuance of long-term debt to finance the acquisition.

Knife River Enters Definitive Deal To Acquire Strata For Purchase Price Of $454M

Northland Capital Markets analyst Bobby Brooks maintains CECO Environmental (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CECO#NASDAQ">CECO</a>) with a Outperform and raises the price target from $35 to $38.

CECO

Northland Capital Markets Maintains Outperform on CECO Environmental, Raises Price Target to $38

Northland Capital Markets analyst Mike Grondahl maintains Legacy Education (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LGCY#AMEX">LGCY</a>) with a Outperform and raises the price target from $10 to $10.5.

LGCY

Northland Capital Markets Maintains Outperform on Legacy Education, Raises Price Target to $10.5

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Celldex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>) with a Buy and maintains $80 price target.

CLDX

HC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $80 Price Target

Westlake Securities analyst Casey Ryan maintains Glimpse Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRAR#NASDAQ">VRAR</a>) with a Buy and raises the price target from $2.65 to $4.67.

VRAR

Westlake Securities Maintains Buy on Glimpse Group, Raises Price Target to $4.67

TSLA: -6% &#x7C; <a href="https://www.benzinga.com//node/42613402">NHTSA Announced Earlier, Tesla Recalls 2024 Cybertruck, 2017-2025 Model 3, And 2020-2025 Model Y For TPMS Warning Light Issue; OTA Fix Released, Owner Notification Letters To Be Mailed Feb. 15, 2025</a>
&nbsp;
NKE: -6% &#x7C; <a href="https://www.benzinga.com//node/42605414">Nike Q2 Earnings: Revenue Beat, EPS Beat, Shares Jump, and then reverse — 'Nike Being Nike Again'</a>
&nbsp;
HUMA: 91% &#x7C; <a href="https://www.benzinga.com//node/42609617">FDA Approves Humacyte's SYMVESS For Treating Extremity Vascular Injuries</a>

Movers

HUMA

Market-Moving News for December 20th

On Thursday, the FDA approved Ionis Pharmaceuticals, Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>) Tryngolza (olezarsen) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), a rare, genetic form of severe hypertriglyceridemia (SHTG) that can <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/n42607141/tryngolza-olezarsen-approved-in-u-s-as-first-ever-treatment-for-adults-living-with-familial-chylom" rel="noreferrer noopener">lead to acute pancreatitis (AP)</a>.
SHTG is&nbsp;a condition where the level of triglycerides (type of fat) in the blood is more than three times the normal level.&nbsp;
Tryngolza is the first-ever&nbsp;FDA-approved treatment that significantly and substantially reduces&nbsp;triglyceride levels in adults with FCS and provides a clinically meaningful reduction in AP events when used with an appropriate diet (≤20 grams of fat per day).
Tryngolza is self-administered via an auto-injector once-monthly.
The FDA approval was based on Phase 3 Balance trial data in adult patients.
In the Balance study, Tryngolza 80 mg demonstrated a statistically significant placebo-adjusted mean reduction in triglyceride levels of 42.5% from baseline to six months (p=0.0084).&nbsp;
Reductions from baseline to 12 months were further improved, with Tryngolza achieving a placebo-adjusted 57% mean triglyceride reduction.&nbsp;
Tryngolza also demonstrated a substantial, clinically meaningful reduction in AP events over 12 months; one patient (5%) experienced one episode of AP in the Tryngolza group compared with seven patients (30%) who experienced 11 total episodes of AP in the placebo group.&nbsp;
Tryngolza will be available in the U.S. before year end.
Olezarsen is currently being evaluated in three Phase 3 clinical trials – CORE, CORE2, and ESSENCE – for SHTG. Olezarsen has not been reviewed or approved for SHTG.
In November, Ionis Pharmaceuticals announced the pivotal Phase 3 study design following alignment with the FDA on ION582 for Angelman syndrome (AS). The trial is expected to start in <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41769886/ionis-announces-pivotal-phase-3-trial-design-for-ion582-in-angelman-syndrome" rel="noreferrer noopener">the first half of 2025</a>.
AS typically presents in infancy and is characterized by profound intellectual disability, impaired verbal abilities, and severe motor impairment.
Price Action: At last check on Friday, IONS stock was up 3.79% at $36.94 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/12/42600482/mercks-investigational-two-drug-regime-for-hiv-meets-primary-goal-in-two-late-stage-trials" target="_blank" rel="noreferrer noopener">Merck&#8217;s Investigational Two-Drug Regime For HIV Meets Primary Goal In Two Late-Stage Trials</a></li>
</ul>

Biotech

Health Care

IONS

FDA Approves Ionis Pharmaceuticals' Rare Genetic Disease Therapy to Lower High-Level Of Fat In Blood

JP Morgan analyst Michael Mueller upgrades Federal Realty Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRT#NYSE">FRT</a>) from Neutral to Overweight and raises the price target from $122 to $125.

Upgrades

JP Morgan Upgrades Federal Realty Investment to Overweight, Raises Price Target to $125

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to dive into the biggest pre-market stock movers for Wednesday morning as we check out all of the hottest news to start the day with!



Moving stocks this morning a partnerships, a public offering, clinical trial news and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Dermata Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/drma-stock-quote/">DRMA</a>) stock is rocketing more than 123% alongside heavy pre-market trading.</li>



<li>Nuzee (NASDAQ:<a href="https://investorplace.com/stock-quotes/nuze-stock-quote/">NUZE</a>) shares are soaring over 75% with strong early morning trading.</li>



<li>Hoth Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/hoth-stock-quote/">HOTH</a>) stock is surging more than 45% <a href="https://www.nasdaq.com/press-release/hoth-therapeutics-partners-lts-therapy-systems-accelerate-novel-alzheimers-treatment">on a new partnership</a> to develop its Alzheimer&rsquo;s treatment.</li>



<li>Allarity Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/allr-stock-quote/">ALLR</a>) shares are increasing over 44% after encouraging investors to <a href="https://finance.yahoo.com/news/allarity-encourages-shareholders-vote-reverse-100000785.html">vote for a reverse stock split</a>.</li>



<li>Regencell Bioscience (NASDAQ:<a href="https://investorplace.com/stock-quotes/rgc-stock-quote/">RGC</a>) stock is heading more than 33% higher alongside strong pre-market trading.</li>



<li>Pieris Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/pirs-stock-quote/">PIRS</a>) shares are rising over 28% after <a href="https://www.nasdaq.com/press-release/palvella-therapeutics-and-pieris-pharmaceuticals-announce-definitive-merger-agreement">announcing a merger agreement</a>.</li>



<li>Bone Biologics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bblg-stock-quote/">BBLG</a>) stock is jumping more than 23% with heavy early morning trading today.</li>



<li>NewGenIvf (NASDAQ:<a href="https://investorplace.com/stock-quotes/nivf-stock-quote/">NIVF</a>) shares are climbing over 22% after providing a <a href="https://www.nasdaq.com/press-release/newgenivf-provides-update-potential-reverse-merger-covirix-2024-07-23">reverse merger update</a>.</li>



<li>Perfect Moment (NYSEMKT:<a href="https://investorplace.com/stock-quotes/pmnt-stock-quote/">PMNT</a>) stock is getting a close to 19% boost after announcing a <a href="https://www.nasdaq.com/press-release/perfect-moment-teams-quiet-platforms-establish-distribution-center-us-2024-07-22">distribution center agreement</a>.</li>



<li>Catheter Precision (NYSEMKT:<a href="https://investorplace.com/stock-quotes/vtak-stock-quote/">VTAK</a>) shares are up more than 16% without any clear news this morning.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Azitra&nbsp;(NYSEMKT:<a href="https://investorplace.com/stock-quotes/aztr-stock-quote/">AZTR</a>) stock is crashing over 73% but only <a href="https://investorplace.com/2024/07/why-is-azitra-aztr-stock-up-315-today/">after a massive rally yesterday</a>.</li>



<li>Conn&rsquo;s (NASDAQ:<a href="https://investorplace.com/stock-quotes/conn-stock-quote/">CONN</a>) shares are plummeting 28% on <a href="https://www.12newsnow.com/article/news/local/texas/conns-reportedly-planning-mass-closures/502-4db60564-6fdd-4ffa-ae26-899bec91f75c">reports of impending store closures</a>.</li>



<li>ATI Physical Therapy (NYSE:<a href="https://investorplace.com/stock-quotes/atip-stock-quote/">ATIP</a>) stock is diving more than 25% without any obvious news this morning.</li>



<li>Verastem (NASDAQ:<a href="https://investorplace.com/stock-quotes/vstm-stock-quote/">VSTM</a>) shares are tumbling over 25% on a <a href="https://finance.yahoo.com/news/verastem-oncology-announces-proposed-public-200500583.html">proposed public offering</a>.</li>



<li>Agape ATP (NASDAQ:<a href="https://investorplace.com/stock-quotes/atpc-stock-quote/">ATPC</a>) stock is taking an almost 24% beating after a rally yesterday.</li>



<li>AtlasClear (NYSEMKT:<a href="https://investorplace.com/stock-quotes/atch-stock-quote/">ATCH</a>) shares are sliding more than 22% despite a lack of news on Wednesday.</li>



<li>Sage Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/sage-stock-quote/">SAGE</a>) stock is dropping over 22% after reporting <a href="https://www.nasdaq.com/press-release/sage-therapeutics-and-biogen-announce-topline-results-phase-2-kinetic-2-study-sage">Phase 2 topline results</a>.</li>



<li>Volato (NYSEMKT:<a href="https://investorplace.com/stock-quotes/soar-stock-quote/">SOAR</a>) shares are decreasing more than 21% <a href="https://www.nasdaq.com/press-release/volato-updates-fractional-program-additional-differentiated-benefits-2024-07-23">after a recent rally</a>.</li>



<li>Chijet Motor (NASDAQ:<a href="https://investorplace.com/stock-quotes/cjet-stock-quote/">CJET</a>) stock is slipping over 19% following yesterday&rsquo;s rally.</li>



<li>Salarius Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/slrx-stock-quote/">SLRX</a>) shares close out our pre-market stock movers down more than 19% after a rally yesterday.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-july-24th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

IPO Roundup: zSpace, Actuate Therapeutics and more

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Perfect Moment (NYSEMKT:<a href="https://investorplace.com/stock-quotes/pmnt-stock-quote/">PMNT</a>) just reported results for the first quarter of 2025.<ul><li>Perfect Moment reported earnings per share of -22 cents.</li><li>The company reported revenue of $974,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/pmnt-stock-earnings-perfect-moment-for-q1-of-2025/">PMNT Stock Earnings: Perfect Moment Reported Results for Q1 2025</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

PMNT Stock Earnings: Perfect Moment Reported Results for Q1 2025

Perfect Moment GAAP EPS of -$0.22

Perfect Moment GAAP EPS of -$0.17, revenue of $3.83M

Perfect Moment (PMNT) has partnered with renowned luxury fashion sales agency, CD Network, to expand its wholesale distribution and bring greater b...

Perfect Moment teams with luxury fashion sales agency, CD Network

Perfect Moment (PMNT) has partnered with United Repair Centre to offer a new bespoke repair service for Perfect Moment customers, Perfect for Longe...

Perfect Moment teams with United Repair Centre to create 'Perfect for Longer'

Perfect Moment (PMNT) received a notification from the NYSE American LLC stating that the Company is not in compliance with the minimum stockholder...

Perfect Moment discloses NYSE notice of listing non-compliance

Perfect Moment receives NYSE notice for non-compliance

Perfect Moment (PMNT) received a notification from the NYSE stating that the company is not in compliance with the minimum stockholders' equity req...

Perfect Moment receives noncompliance notification from NYSE

ACTU

ALLR

ATCH

ATIP

ATPC

AZTR

BBLG

CJET

CONN

DMAAU

DRIL

DRMA

EMTX

HLXB

HOTH

KYTX

NIVF

NUZE

OSTX

PIRS

PLMKU

PMNT

SAGE

SLRX

SOAR

TBBB

TELO

VACHU

VSTM

VTAK

ZSPC

Emerging Markets

Movers & Shakers

After February IPO, Functional Fashion Firm Perfect Moment Targets Growth And Expansion In Ski Wear And Other Categories, Launches First U.S. Distribution Center

Press Releases

Perfect Moment to Present at Investor Conferences in October

Perfect Moment Appoints Top Fashion Executive, Rosela Mitropoulos, to Head of Business Development and Lead Global Multi-Channel Expansion

Perfect Moment Reports Fiscal Q2 2025 Results

Perfect Moment to Present at the ROTH Deer Valley Investor Conference

Perfect Moment Partners with Luxury Fashion Agency, CD Network, to Expand Wholesale Distribution in North America

Perfect Moment and United Repair Centre Join Forces to Launch New Repair Service, 'Perfect for Longer,' Across UK and Europe

Perfect Moment Opens First European Seasonal Store at World-Renowned Austrian Alps Ski Resort

Perfect Moment Elevates Brand Worldwide in Multi-Million Dollar Co-Marketing Campaign with World's #1 Scotch Whisky Maker, Johnnie Walker

Comments

Perfect Moment

Interés en corto

Perfect Moment (AMEX:PMNT) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL